MetaCap

Arrowhead Pharmaceuticals (ARWR) vs Ligand Pharmaceuticals (LGND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ligand Pharmaceuticals (LGND) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 44.0% versus a gain of 2.3%. Over five years, LGND leads with a +193.2% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $5.74 billion), about 1.0 times the size, while Ligand Pharmaceuticals is growing revenue faster (+60.4% vs -45.6%).

Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus -160.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARWR+2.27%LGND+43.98%
+128%+56%-15%
Nov 21, 20251 yearNov 20, 2026
ARWR-41.82%LGND+183.98%
+235%+67%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARWR versus LGND key metrics
MetricARWRLGND
Share price$41.37$286.85
Market cap$5.85B$5.74B
1-day change-5.22%-0.03%
YTD return-37.69%+51.72%
1-year return+2.27%+43.98%
5-year return-42.56%+193.16%
P/E ratio (TTM)—115.20
Forward P/E—24.00
EPS (TTM)$-5.11$2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$450.82M$268.09M
Revenue growth (YoY)-45.65%+60.40%
Net income (latest FY)$-724.21M$124.45M
Operating margin-156.86%15.29%
Net margin-160.64%46.42%
52-week high$95.49$326.63
52-week low$40.43$175.89
Distance from 52-week high-56.68%-12.18%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+156.39%+25.94%
Average volume2.08M230.79K
Shares outstanding141.37M20.00M
Employees1,06247
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LGND has outperformed ARWR by 41.7 percentage points over the past year.
  • Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
  • Ligand Pharmaceuticals grew revenue faster in its latest fiscal year (+60.40% vs -45.65%).

About Arrowhead Pharmaceuticals

ARWR stock →

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees

About Ligand Pharmaceuticals

LGND stock →

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

ARWR vs LGND FAQ

Which is bigger, Arrowhead Pharmaceuticals or Ligand Pharmaceuticals?

Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $5.74B for Ligand Pharmaceuticals (LGND).

Which stock has performed better over the past year, ARWR or LGND?

LGND returned +43.98% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.

Are Arrowhead Pharmaceuticals and Ligand Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons